TriSalus Life Sciences (TLSI) Depreciation & Amortization (CF) (2022 - 2026)

TriSalus Life Sciences has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $135000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 21.51% year-over-year to $135000.0; the trailing twelve-month figure through Mar 2026 stood at $589000.0 (down 20.51% YoY), and the FY2025 full-year result was $626000.0, down 15.86% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $135000.0, up from $126000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $194000.0 in Q4 2023, with the low at -$54000.0 in Q4 2022.
• Historically, Depreciation & Amortization (CF) has averaged $152500.0 across 5 years, with a median of $168500.0 in 2025.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 459.26% — and 2025, when it tumbled 34.72%.
• TriSalus Life Sciences' Depreciation & Amortization (CF) stood at -$54000.0 in 2022, then surged by 459.26% to $194000.0 in 2023, then retreated by 0.52% to $193000.0 in 2024, then plunged by 34.72% to $126000.0 in 2025, then increased by 7.14% to $135000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $135000.0 (Q1 2026), $126000.0 (Q4 2025), and $163000.0 (Q3 2025), per Business Quant data.